# H. Guo

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/h-guo/

## Facts

| Field | Value |
| --- | --- |
| Citations | 0 |
| Field | Prostate Cancer Diagnosis and Treatment |
| h-index | 0 |
| i10-index | 0 |
| Last Known Institution | Nanjing Drum Tower Hospital |
| OpenAlex ID | https://openalex.org/A5121064244 |
| Works | 6 |

## Researcher papers

- [490MO Niraparib (NIRA) and abiraterone acetate plus prednisone (AAP) in Chinese patients with breast cancer susceptibility gene (BRCA) altered metastatic castration-sensitive prostate cancer (mCSPC): Subgroup analysis of the phase III AMPLITUDE trial](https://scholariq.org/papers/490mo-niraparib-nira-and-abiraterone-acetate-plus-prednisone-aap-in-chinese/)
- [573P Anatomical adaptability guides approach selection in robotic partial nephrectomy: Equivalent trifecta outcomes with route-specific predictive models](https://scholariq.org/papers/573p-anatomical-adaptability-guides-approach-selection-in-robotic-partial/)
- [574P SHOX2-Mediated lymphatic metastasis in pT1 non-clear cell renal carcinoma: Biomarker-driven risk stratification and combined-modality management](https://scholariq.org/papers/574p-shox2-mediated-lymphatic-metastasis-in-pt1-non-clear-cell-renal-carcinoma/)
- [498P Efficacy and safety of triptorelin pamoate 22.5 mg 6-month formulation in Chinese patients with locally advanced or metastatic prostate cancer: A multicentre, single-arm phase IIIb study](https://scholariq.org/papers/498p-efficacy-and-safety-of-triptorelin-pamoate-22-5-mg-6-month-formulation-in/)
- [489MO A multicenter, single-arm, phase II trial of androgen deprivation therapy in combination with apalutamide in patients with high risk of recurrence after radical prostatectomy (ARES study)](https://scholariq.org/papers/489mo-a-multicenter-single-arm-phase-ii-trial-of-androgen-deprivation-therapy-in/)
- [Neoadjuvant pamiparib plus abiraterone and androgen deprivation therapy for high-risk/very high-risk localized prostate cancer: an open-label, single-arm, phase 2 study](https://scholariq.org/papers/neoadjuvant-pamiparib-plus-abiraterone-and-androgen-deprivation-therapy-for-high/)

## Researcher topics

- [Prostate Cancer Diagnosis and Treatment](https://scholariq.org/topics/prostate-cancer-diagnosis-and-treatment/)
- [Prostate Cancer Treatment and Research](https://scholariq.org/topics/prostate-cancer-treatment-and-research/)
- [Urinary Bladder and Prostate Research](https://scholariq.org/topics/urinary-bladder-and-prostate-research/)
- [Renal cell carcinoma treatment](https://scholariq.org/topics/renal-cell-carcinoma-treatment/)
- [PARP inhibition in cancer therapy](https://scholariq.org/topics/parp-inhibition-in-cancer-therapy/)

## Researcher university

- [Nanjing Drum Tower Hospital](https://scholariq.org/institutions/nanjing-drum-tower-hospital/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.